FYN is a major downstream target of ABL1 in human leukemias (Ban et al., 2008; Singh et al., 2012) and LYN signaling promotes resistance to ABL1 inhibitors (Donato et al., 2003; Ingley, 2012; Ptasznik et al., 2004). This evidence concerns the gene FYN and leukemia.